RNA interference (RNAi) offers a promising approach for AML patients with FLT3-ITD mutations, addressing challenges like drug resistance and high relapse rates. Lipopolymers have demonstrated efficacy ...

The discovery of RNAi dates back to the 1990s when researchers observed unexpected gene silencing in plants and fungi. In 1998, Andrew Fire and Craig Mello published a groundbreaking study ...

A new possibility for managing cardiovascular disease through RNA interference (RNAi) gene therapies. As cardiovascular diseases continue to be the leading cause of death globally, this technology ...

Using RNA to interfere with a gene’s expression of disease-causing proteins is a validated therapeutic approach, but so far, the products in this drug class only address liver proteins. Reducing ...

Silence Therapeutics focuses on RNA interference therapies, with its lead candidates targeting cardiovascular and hematological diseases via the mRNAi GOLD platform. Zerlasiran, the company’s main ...

RNAi combined with optimized delivery technology To specifically target the mold Aspergillus fumigatus, the researchers combined an RNAi approach with optimized delivery technology from nanomedicine.

The vector consists of a polyethylene glycolylated liposomal outer coat (providing immune evasion and prolonged circulation), a spindle-shaped nanomotor (resembling a flagellum, facilitating targeted ...

RNA interference – RNAi – functions specifically to silence, or deactivate, genes. Among other applications, it promises to be groundbreaking as a way to treat infections of bees by a commercially ...

Discover how AI is revolutionizing RNA drug development in a new article published in Engineering. Learn about the potential ...